Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in at ...

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...

Bio-Rad Laboratories ( (BIO) ) has shared an announcement.

Bio-Rad Laboratories Inc (NYSE:BIO) presented its second quarter 2025 financial results on July 31, showing modest revenue growth despite ongoing margin challenges and regional market headwinds. The ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

日水製薬株式会社（本社：東京都台東区、代表取締役社長執行役員：小野徳哉）は、新たな成長分野への積極的投資の一環として、バイオ・ラッド ラボラトリーズ株式会社（本社：東京都品川区、代表取締役社長：奥田哲人、以下「バイオ・ラッド」）の ...

The CFX Opus 96 Dx System and the CFX Opus 384 Dx Real-Time PCR Systems Offer Accurate and Precise Quantification to Improve IVD Assay Development and Diagnostic Testing Bio-Rad experts Eddy van ...